01.08.2013 Views

Education and Training in Autism and Developmental Disabilities

Education and Training in Autism and Developmental Disabilities

Education and Training in Autism and Developmental Disabilities

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

TABLE 5<br />

ERDCP: Means, SDs, <strong>and</strong> t Test, Number of Participants Above the Suggested Cut-off Accord<strong>in</strong>g Relocation<br />

ERDCP Sub-Scales<br />

the nerve sedatives family (MH 15, p <br />

.001). Furthermore, a Wilcoxon test reveals<br />

that the two related distributions are different<br />

(Z 5.446, p .001). For the anxiolitic<br />

medication family, analysis reveals that<br />

changes between Time 2 <strong>and</strong> Time 1 are also<br />

Not Relocated (N 71) Relocated (N 65)<br />

T1 T3 t T1 T3 t<br />

Agressiveness 1.28 (1.93) .69 (1.3) 2.74** 1.38 (2.03) 1.2 (2.01) .58<br />

<strong>Autism</strong> .53 (.93) .39 (.70) 1.76 .82 (1.18) .49 (.85) 1.90<br />

Psychosis .41 (.97) .23 (.75) 2.10* .64 (1.42) .48 (1.18) .87<br />

Paranoia .59 (1.0) .31 (.73) 2.79** .71 (1.32) .62 (1.25) .41<br />

Depression (behavioral signs) .69 (1.17) .58 (.97) .76 1.16 (1.64) .84 (1.43) .35<br />

Depression (physical signs) .48 (.89) .53 (.96) .30 .8 (1.21) .74 (1.12) .35<br />

Dependent personality .72 (1.11) .53 (.94) 1.45 1 (1.34) .85 (1.25) .76<br />

Avoidance disorder .58 (1.01) .51 (.02) .53 .75 (1.41) .61 (1.04) .71<br />

ERDCP Items<br />

Alcohol/Drug abuse 0 0 – 0 (0) 0 (0) –<br />

Hyperactivity .05 (.23) .04 (.26) .58 .22 (.57) .09 (.29) 1.59<br />

Self-mutilation .21 (.48) .20 (.4) .24 .28 (.57) .32 (.56) .52<br />

Inappropriate sexual behaviors .11 (.4) .06 (.23) 1.42 .03 (.17) .03 (.17) –<br />

Robbery .2 (.52) .14 (.42) 1.27 .15 (.44) .15 (.44) –<br />

Suicidal tendancies 0 0 – 0 (0) .03 (.17) 1.45<br />

Total ERDCP scale (26 items) 4.75 (6.09) 3.38 (4.52) 1.93 6.46 (7.93) 5.31 (6.42) 1.00<br />

* p .05, ** p .01, *** p .001.<br />

TABLE 6<br />

Evolution of Medication Between Time 1 <strong>and</strong> Time 2<br />

significant (MH 14, p .05). The Wilcoxon<br />

test also shows <strong>in</strong> that case that the two distributions<br />

are different (Z 2.416, p .05).<br />

Medication <strong>and</strong> maladaptive behaviors or mental<br />

health problems. The relation between medication’s<br />

evolution (difference between Time 1<br />

Drugs Type <strong>and</strong> Daily Posology <strong>in</strong> Miligram Number of People Medication Evolution<br />

Nerve sedative (antipsychotic)<br />

CPZ equivalence<br />

(Daily posology)<br />

Anxiolytic (benzodiazep<strong>in</strong>e)<br />

Diazépam equivalence<br />

(Daily posology)<br />

Total 136 134<br />

Time 1 Time 2 Decrease Stable Increase<br />

0 mg 98 68 5 (3.8%) 74 (55.6%) 54 (40.6%)<br />

1–15 mg 8 7<br />

16–59 mg 6 12<br />

60 mg or 24 46<br />

Total 136 133<br />

0 mg 119 108 8 (6%) 107 (80%) 19 (14%)<br />

1–15 mg 10 16<br />

16–59 mg 4 7<br />

60 mg or 3 3<br />

Note. At Time 2: Miss<strong>in</strong>g data for three participants concern<strong>in</strong>g nerve sedative <strong>and</strong> for two participants<br />

concern<strong>in</strong>g anxiolytic.<br />

372 / <strong>Education</strong> <strong>and</strong> <strong>Tra<strong>in</strong><strong>in</strong>g</strong> <strong>in</strong> <strong>Autism</strong> <strong>and</strong> <strong>Developmental</strong> <strong>Disabilities</strong>-September 2010

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!